Transforming Wound Care and Dermatology

BioMendics, LLC^® is dedicated to the treatment of rare genetic skin disorders, acute wounds, burns, antibiotics, and inflammatory skin conditions. The company’s lead product in development, TolaSure^™, is a patented topical gel containing small-molecule liquid crystals that help promote all phases of the healing process and interact with the skins naturally occurring electrical currents of injury for enhanced proliferation and directed cell migration.

BioMendics is currently recruiting for a clinical study: A Phase I/IIa, Closed Label, Randomized, Pilot Study for the Safety and Efficacy of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES), at Stanford University Department of Dermatology under the direction of Dr. Albert Chiou, Dr. Jean Tang, and Dr. Joyce Teng. Learn more at clinicaltrials.gov and contact the Stanford study site directly or contact BioMendics at info@biomendics.com.